大规模蛋白质组学改善糖尿病患者慢性肾脏病预测
基于英国生物银行药物蛋白质组学项目中2094例基线无慢性肾脏病史的糖尿病患者,构建了包含11种血浆蛋白的慢性肾脏病蛋白风险评分。在中位随访12.1年的测试集中,该评分与慢性肾脏病发生正相关(每增加1个标准差,风险比1.78,95%CI 1.44-2.20),将其加入已验证的临床风险模型可显著改善判别与重分类。
要点
- 在糖尿病患者中,11蛋白慢性肾脏病蛋白风险评分与慢性肾脏病发生正相关(每增加1个标准差,风险比1.78,95%CI 1.44-2.20)。
- 将蛋白风险评分加入慢性肾脏病预测联盟风险因素后C指数最高达0.825(95%CI未报告),较0.802提高0.023(95%CI 0.006-0.044)。
- 慢性肾脏病多基因风险评分对预测改善无显著作用(C指数增加0.007,95%CI -0.016-0.025)。
核心结论
- 将慢性肾脏病蛋白风险评分加入已验证的临床风险模型,可显著改善糖尿病患者慢性肾脏病风险的判别与重分类。
研究设计与样本
- 队列研究,纳入英国生物银行药物蛋白质组学项目中2094例基线无慢性肾脏病史且有蛋白质组学与遗传信息的糖尿病患者。
- 基于近3000种血浆蛋白,在训练集(1047例参与者,117例慢性肾脏病事件)中构建包含11种蛋白的慢性肾脏病蛋白风险评分。
- 测试集包含1047例参与者,112例慢性肾脏病事件,中位随访12.1年。
主要发现
- 测试集中,慢性肾脏病蛋白风险评分与慢性肾脏病发生正相关(每增加1个标准差,风险比1.78,95%CI 1.44-2.20)。
- 与基础模型(年龄+性别+种族,C指数0.627,95%CI 0.578-0.675)相比,蛋白风险评分C指数增加0.122(95%CI 0.071-0.177),慢性肾脏病预测联盟风险因素C指数增加0.175(95%CI 0.126-0.217),均显著改善预测性能。
- 慢性肾脏病多基因风险评分C指数增加0.007(95%CI -0.016-0.025),无显著改善。
- 将蛋白风险评分加入慢性肾脏病预测联盟风险因素后C指数最高为0.825(C指数从0.802升至0.825;差值0.023;95%CI 0.006-0.044),并显著改善连续10年净重分类(0.199;95%CI 0.059-0.299)和10年综合判别指数(0.041;95%CI 0.007-0.083)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate a protein risk score for predicting chronic kidney disease (CKD) in patients with diabetes and compare its predictive performance with a validated clinical risk model (CKD Prediction Consortium [CKD-PC]) and CKD polygenic risk score. RESEARCH DESIGN AND METHODS: This cohort study included 2,094 patients with diabetes who had proteomics and genetic information and no history of CKD at baseline from the UK Biobank Pharma Proteomics Project. Based on nearly 3,000 plasma proteins, a CKD protein risk score including 11 proteins was constructed in the training set (including 1,047 participants; 117 CKD events). RESULTS: The median follow-up duration was 12.1 years. In the test set (including 1,047 participants; 112 CKD events), the CKD protein risk score was positively associated with incident CKD (per SD increment; hazard ratio 1.78; 95% CI 1.44, 2.20). Compared with the basic model (age + sex + race, C-index, 0.627; 95% CI 0.578, 0.675), the CKD protein risk score (C-index increase 0.122; 95% CI 0.071, 0.177), and the CKD-PC risk factors (C-index increase 0.175; 95% CI 0.126, 0.217) significantly improved the prediction performance of incident CKD, but the CKD polygenic risk score (C-index increase 0.007; 95% CI -0.016, 0.025) had no significant improvement. Adding the CKD protein risk score into the CKD-PC risk factors had the largest C-index of 0.825 (C-index from 0.802 to 0.825; difference 0.023; 95% CI 0.006, 0.044), and significantly improved the continuous 10-year net reclassification (0.199; 95% CI 0.059, 0.299) and 10-year integrated discrimination index (0.041; 95% CI 0.007, 0.083). CONCLUSIONS: Adding the CKD protein risk score to a validated clinical risk model significantly improved the discrimination and reclassification of CKD risk in patients with diabetes.
引用
- Ye Z, Zhang Y, Zhang Y, et al. Large-Scale Proteomics Improve Prediction of Chronic Kidney Disease in People With Diabetes. Diabetes Care. 2024. PMID: 39042512. doi:10.2337/dc24-0290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。